 |
|
Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
May 16, 2008Study to be presented at the American Society of Clinical Oncology
ROCHESTER, Minn. -- Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive intravenous calcium and magnesium before and after the chemotherapy drug oxaliplatin for the treatment of advanced colon cancer experience a significantly reduced incidence and severity of neurological side effects (neurotoxicity). This reduction increases the likelihood that patients are able to complete a full course of treatment. The findings were released May 15 as part of the 44th annual meeting of the American Society of Clinical Oncology.
"There have been limited studies and anecdotal stories about the effectiveness of calcium plus magnesium in reducing neurotoxicity caused by oxaliplatin," says Daniel Nikcevich, M.D., Ph.D., an oncologist at St. Mary's Duluth Clinic in Duluth, Minn., a member of NCCTG and study co-chair.
"We designed a double-blind, placebo-controlled study that confirmed the effectiveness of calcium plus magnesium in reducing debilitating neurological sensitivity associated with oxaliplatin, such as pain in the hands, fingers, feet and toes. In the past, these side effects have caused patients to stop treatment and, therefore, not receive critical therapy."
Each year in the United States, 150,000 patients are diagnosed with colon cancer, and approximately 50 percent of those develop advanced colon cancer. Oxaliplatin, in combination with other chemotherapy drugs such as 5-fluorouracil (5-FU), has emerged as a standard-of-care of first-line therapy for advanced colon cancer. However, oxaliplatin can cause both acute and chronic cumulative sensory neurological problems including pain, numbness and tingling that can prevent patients from completing treatment.
In the study, 50 of the 102 patients enrolled received intravenous calcium and magnesium along with oxaliplatin-based chemotherapy, while 52 patients received oxaliplatin-based adjuvant chemotherapy for colon cancer and an intravenous placebo. Study results showed that the use of calcium and magnesium infusions before and after oxaliplatin was associated with a significant decrease in the incidence and severity of neurotoxicity, and it also delayed the time to the onset of neurotoxicity on oxaliplatin therapy.
Calcium and magnesium are an easily administered, safe treatment option for oxaliplatin-induced neurotoxicity. "Some initial reports from other studies claimed that the use of calcium and magnesium reduced the activity of oxaliplatin-based chemotherapy," says Axel Grothey, M.D., an oncologist at Mayo Clinic and study co-chair. "However, we have definitive results from an independent, blinded radiologic review which demonstrates no negative influence of calcium and magnesium on the outcome for oxaliplatin-based chemotherapy."
"Now that we have shown the effectiveness of calcium and magnesium in reducing oxaliplatin-induced neurotoxicity, a further step may be to evaluate the benefit of calcium and magnesium in reducing neurotoxicity caused by other medications," says Dr. Nikcevich. "Many other commonly used chemotherapy agents cause neurological sensitivity. By applying our study design, we can test the effectiveness of calcium and magnesium when used with other treatments."
This study was done as part of a program coordinated by Charles Loprinzi, M.D., a medical oncologist at Mayo Clinic Rochester. The program he leads has conducted more than 50 clinical trials designed to find ways to prevent or treat untoward symptoms related to cancer and cancer therapy. This includes three trials to evaluate ways to treat established neuropathy caused by chemotherapy and three additional studies to try to prevent such toxicity. Additional trials are in development to find other ways to alleviate this toxicity.
Mayo Clinic
"We designed a double-blind, placebo-controlled study that confirmed the effectiveness of calcium plus magnesium in reducing debilitating neurological sensitivity associated with oxaliplatin, such as pain in the hands, fingers, feet and toes. In the past, these side effects have caused patients to stop treatment and, therefore, not receive critical therapy."
Each year in the United States, 150,000 patients are diagnosed with colon cancer, and approximately 50 percent of those develop advanced colon cancer. Oxaliplatin, in combination with other chemotherapy drugs such as 5-fluorouracil (5-FU), has emerged as a standard-of-care of first-line therapy for advanced colon cancer. However, oxaliplatin can cause both acute and chronic cumulative sensory neurological problems including pain, numbness and tingling that can prevent patients from completing treatment.
In the study, 50 of the 102 patients enrolled received intravenous calcium and magnesium along with oxaliplatin-based chemotherapy, while 52 patients received oxaliplatin-based adjuvant chemotherapy for colon cancer and an intravenous placebo. Study results showed that the use of calcium and magnesium infusions before and after oxaliplatin was associated with a significant decrease in the incidence and severity of neurotoxicity, and it also delayed the time to the onset of neurotoxicity on oxaliplatin therapy.
Calcium and magnesium are an easily administered, safe treatment option for oxaliplatin-induced neurotoxicity. "Some initial reports from other studies claimed that the use of calcium and magnesium reduced the activity of oxaliplatin-based chemotherapy," says Axel Grothey, M.D., an oncologist at Mayo Clinic and study co-chair. "However, we have definitive results from an independent, blinded radiologic review which demonstrates no negative influence of calcium and magnesium on the outcome for oxaliplatin-based chemotherapy."
"Now that we have shown the effectiveness of calcium and magnesium in reducing oxaliplatin-induced neurotoxicity, a further step may be to evaluate the benefit of calcium and magnesium in reducing neurotoxicity caused by other medications," says Dr. Nikcevich. "Many other commonly used chemotherapy agents cause neurological sensitivity. By applying our study design, we can test the effectiveness of calcium and magnesium when used with other treatments."
This study was done as part of a program coordinated by Charles Loprinzi, M.D., a medical oncologist at Mayo Clinic Rochester. The program he leads has conducted more than 50 clinical trials designed to find ways to prevent or treat untoward symptoms related to cancer and cancer therapy. This includes three trials to evaluate ways to treat established neuropathy caused by chemotherapy and three additional studies to try to prevent such toxicity. Additional trials are in development to find other ways to alleviate this toxicity.
Mayo Clinic
Neurotoxicity News and Current Neurotoxicity Events RSSHow chemo kills tumours: research to reduce side effects
Dr Stephen Taylor and Karen Gascoigne at the University's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK.
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
Chemotherapy causes delayed severe neural damage
Cancer treatment with chemotherapeutic agents is often associated with delayed adverse neurological consequences - an occurrence often referred to as "chemobrain" - that may compromise the quality of life of a proportion of cancer survivors.
Blood pressure drug curbs brain damage from PTSD
A drug used to treat high blood pressure and enlargement of the prostate may protect the brain from damage caused by post-traumatic stress disorder, Alzheimer's disease, depression and schizophrenia.
A study undertaken at the University of Navarra relates the neural damage provoked by Ecstasy with the ambient temperature at which it is consumed
There exists a direct relationship between the consumption of MDMA, or Ecstasy, at a high ambient temperature and an increase in the neural damage which this drug provokes.
Scripps research study links chronic methamphetamine abuse and cardiovascular disease
In recent years, the spread of methamphetamine abuse across the United States has been as rapid as it has been alarming. Until about six years ago, methamphetamine use was seen mostly in the western and rural United States.
A silent pandemic: Industrial chemicals are impairing the brain development of children worldwide
Fetal and early childhood exposures to industrial chemicals in the environment can damage the developing brain and can lead to neurodevelopmental disorders (NDDs)-autism, attention deficit disorder (ADHD), and mental retardation.
A Novel Mechanism of Manganese-Induced Neurological Dysfunction Discovered
For decades, scientists have known that chronic exposure to high concentrations of the metal manganese can cause movement abnormalities resembling symptoms of Parkinson's disease, but apparently without the same neuron damage characteristic of Parkinson's patients.
Promising therapy for ALS delivers antisense drug directly to nervous system
Researchers from the University of California, San Diego (UCSD) School of Medicine, the Center for Neurologic Study and Isis Pharmaceutical Corporation have designed and tested a molecular therapy in animals that they hope will be a major development in the fight to treat amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.
Study finds a high caloric diet may prevent the progression of amyotrophic lateral sclerosis
A recent study directed by the Mount Sinai School of Medicine suggests a ketogenic- high caloric diet may prevent the progression of Amyotrophic Lateral Sclerosis (ALS).
More Neurotoxicity News Articles
 | Neurotoxicity Guidebook by Raymond Singer |
| Neurotoxicity: Identifying and Controlling Poisons of the Nervous System : New Developments in Neuroscience by U S Congress Office of Tech, Office Of Technology A. U. S. Congress | |
| Current Status of Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity (Annals of the New York Academy of Sciences) | |
 | Solvent Neurotoxicity by Peter Arlien-Soborg Solvent Neurotoxicity presents a comprehensive summary of the latest information available regarding acute and chronic neurotoxicity of a number of solvents. Ten solvents (Chloromethane; Dichloromethane; N-Hexane; Methyl Ethyl Ketone; Methyln N-Butyl Ketone; Styrene; Toluene; 1,1,1-Trichloroethane, Trichloroethylene, and Xylene) and two mixtures of solvents (White Spirit, Mixed solvent exposure)... |
 | The Role of Glia in Neurotoxicity by Michael Aschner, Harold K. Kimelberg It is well established that glial cells represent more than mere passive cytoskeletal support elements of the central and peripheral nervous system. A reciprocal relationship exists between neurons and glia that is vital for mutual differentiation, development, and functioning of both cell types. It also has become apparent that perturbations in glial function may lead to deleterious consequences... |
 | Site-Selective Neurotoxicity (Cellular and Molecular Mechanisms of Toxic Action) This unique volume provides interdisciplinary coverage of the mechanistic perspective of neurotoxicity that focuses on the site of action of known neurotoxins. It provides the reader with an insight into the common characteristics of neurotoxin action on the nervous system and examines sites of action at three levels of complexity: molecular, cellular, and brain, which will allow the development... |
| Neurotoxicity of the visual system | |
| Failure to produce arsenic neurotoxicity in the rat: An experimental study (EPA 560/11-80-022) by Herbert H Schaumburg | |
| Neurotoxicity Testing of Organic Solvents in Laboratory Animals: Proceedings of Workshop in Copenhagen 8.-9. June 1995 (TemaNord 1996:531) by Nordic Environmental Cooperation | |
| The Use of cell culture for evaluating neurotoxicity by Bellina Veronesi |
| © 2008 BrightSurf.com |